A 6-week open-label, randomized, multicentre, phase IIIb, parallel-group study, which describes the renal effects of the lipid-regulating agents rosuvastatin and simvastatin in the treatment of subjects with Fredrickson type IIa and IIb dyslipidaemia, including heterozygous familial hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2006
At a glance
- Drugs Rosuvastatin; Simvastatin
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Pharmacodynamics
- 28 Mar 2006 New trial record.